Auditory neuropathy in mice and humans with Friedreich ataxia
Annals of Clinical and Translational Neurology · 2023
DOI: 10.1002/acn3.51777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Gary Rance und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Audiology and Speech Pathology, The University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Friedreich Ataxia, Hearing Loss, Central. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Recent studies have found that human Friedreich ataxia patients have dysfunction of transmission in the auditory neural pathways. Here, we characterize hearing deficits in a mouse model of Friedreich ataxia and compare these to a clinical population.
Methods
Sixteen mice with a C57BL/6 background were evaluated. Eight were YG8Pook/J animals (Friedreich ataxia phenotype) and eight wild‐type mice served as controls. Auditory function was assessed between ages 6 and 12 months using otoacoustic emissions and auditory steady‐state responses. At study end, motor deficit was assessed using Rotorod testing and inner ear tissue was examined. Thirty‐seven individuals with Friedreich ataxia underwent auditory steady‐state evoked potential assessment and response amplitudes were compared with functional hearing ability (speech perception‐in‐noise) and disease status was measured by the Friedreich Ataxia Rating Scale.
Results
The YG8Pook/J mice showed anatomic and functional abnormality. While otoacoustic emission responses from the cochlear hair cells were mildly affected, auditory steady‐state responses showed exaggerated amplitude reductions as the animals aged with Friedreich ataxia mice showing a 50–60% decrease compared to controls who showed only a 20–25% reduction ( F (2,94) = 17.90, p < 0.00). Furthermore, the YG8Pook/J mice had fewer surviving spiral ganglion neurons, indicating greater degeneration of the auditory nerve. Neuronal density was 20–25% lower depending on cochlear region ( F (1, 30) = 45.02, p < 0.001). In human participants, auditory steady‐state response amplitudes were correlated with both Consonant–Nucleus–Consonant word scores and Friedreich Ataxia Rating Scale score.
Interpretation
This study found degenerative changes in auditory structure and function in YG8Pook/J mice, indicating that auditory measures in these animals may provide a model for testing Friedreich ataxia treatments. In addition, auditory steady‐state response findings in a clinical population suggested that these scalp‐recorded potentials may serve as an objective biomarker for disease progress in affected individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Audiology and Speech Pathology, The University of Melbourne, Melbourne, Victoria, Australia.
- Department of Otolaryngology, University of Melbourne, Melbourne, Victoria, Australia.
- Victorian Clinical Genetics Services, Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- Ear Science Institute Australia, Perth, Western Australia, Australia.
ORCID-Profile: Gary Rance
Zitieren
APA
Rance, G., Carew, P., Winata, L., Sale, P., Delatycki, M., & Sly, D. (2023). Auditory neuropathy in mice and humans with Friedreich ataxia. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51777
Vancouver
Rance G, Carew P, Winata L, Sale P, Delatycki M, Sly D. Auditory neuropathy in mice and humans with Friedreich ataxia. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51777
BibTeX
@article{Rance2023,
author = {Rance, Gary and Carew, Peter and Winata, Leon and Sale, Phillip and Delatycki, Martin and Sly, David},
title = {Auditory neuropathy in mice and humans with Friedreich ataxia},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
doi = {10.1002/acn3.51777}
}
EUVIMED